Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

New age of neuroproteomics in Alzheimer's disease research.

Kovacech B, Zilka N, Novak M.

Cell Mol Neurobiol. 2009 Sep;29(6-7):799-805. doi: 10.1007/s10571-009-9358-6. Review.

PMID:
19225878
2.
3.

Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.

Pei JJ, Sjögren M, Winblad B.

Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b. Review.

PMID:
18852562
4.

Truncation of tau protein and its pathological significance in Alzheimer's disease.

García-Sierra F, Mondragón-Rodríguez S, Basurto-Islas G.

J Alzheimers Dis. 2008 Aug;14(4):401-9. Review.

PMID:
18688090
5.

Regulation of tau phosphorylation in Alzheimer's disease.

Lee VM.

Ann N Y Acad Sci. 1996 Jan 17;777:107-13. Review.

PMID:
8624072
6.

Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies.

Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2005 Jan;109(1):25-31. Review.

PMID:
15645264
7.

Tau therapeutics for Alzheimer's disease: the promise and the challenges.

Gold M.

J Mol Neurosci. 2002 Dec;19(3):331-4. Review.

PMID:
12540060
8.

Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.

Iqbal K, Grundke-Iqbal I.

Curr Drug Targets. 2004 Aug;5(6):495-502. Review.

PMID:
15270196
9.

Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology.

Obulesu M, Venu R, Somashekhar R.

Neurochem Res. 2011 Aug;36(8):1329-35. doi: 10.1007/s11064-011-0475-5. Review.

PMID:
21509508
10.

Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease.

Hernández F, Lim F, Lucas JJ, Pérez-Martín C, Moreno F, Avila J.

Mini Rev Med Chem. 2002 Feb;2(1):51-8. Review.

PMID:
12369957
11.

Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies.

Zilka N, Kontsekova E, Novak M.

J Alzheimers Dis. 2008 Oct;15(2):169-79. Review.

PMID:
18953106
12.

Aberrant phosphorylation in the pathogenesis of Alzheimer's disease.

Chung SH.

BMB Rep. 2009 Aug 31;42(8):467-74. Review.

13.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. Review.

PMID:
21605038
14.

Current strategies for the treatment of Alzheimer's disease and other tauopathies.

Dickey CA, Petrucelli L.

Expert Opin Ther Targets. 2006 Oct;10(5):665-76. Review.

PMID:
16981824
15.

Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.

Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N, Khatoon S, Pei JJ, Tsujio I, Wang JZ, Grundke-Iqbal I.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):95-9. Review.

PMID:
12212801
16.

[From physiopathology to treatment of Alzheimer's disease].

Delacourte A.

Rev Neurol (Paris). 2006 Oct;162(10):909-12. Review. French.

PMID:
17028557
17.

[Phosphorylation of tau and Alzheimer's disease].

García T, Jay D.

Gac Med Mex. 2004 May-Jun;140(3):329-33. Review. Spanish.

PMID:
15259345
18.

Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration.

Sahara N, Maeda S, Takashima A.

Curr Alzheimer Res. 2008 Dec;5(6):591-8. Review.

PMID:
19075586
19.

The role of tau phosphorylation and cleavage in neuronal cell death.

Chun W, Johnson GV.

Front Biosci. 2007 Jan 1;12:733-56. Review.

PMID:
17127334
20.

Assessing the toxicity of tau aggregation.

Rankin CA, Gamblin TC.

J Alzheimers Dis. 2008 Aug;14(4):411-6. Review.

PMID:
18688091

Supplemental Content

Support Center